Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Ottobock raises 2026 outlook for core business after strong second quarter

Ottobock reported organic revenue growth of 9.7% in the second quarter (core business +10.7%) and adjusted EBITDA of €122.7 million (+23%) with a margin of 27.9%. Net profit rose to €48.5 million. Management raised the revenue guidance for the core business to +6–8% and now expects an adjusted EBITDA margin of more than 27% (previously >26.5%). The stock turned negative in the afternoon after initial gains. » Plus sur finanzen.net
Ottobock raises forecast after strong H1 figures, shares rise

Ottobock reported a Q2 revenue increase of 9.7% to €458.1m and an adjusted EBITDA of €127.1m (+22%), both above the analyst consensus. The company raised its forecast for organic core sales growth in 2026 to 6–8% (previously 5–8%). Quarterly net profit rose from €11.9m to €48.5m, but remained slightly below the Visible Alpha consensus. The stock climbed intraday by 2.7% to €60.50, reaching a daily high of €62.60. » Plus sur de.investing.com
Jefferies keeps Ottobock on Buy and confirms price target of €83

Jefferies confirms, after acquiring Fesia Technology, its rating for Ottobock at "Buy" with a price target of €83. The acquisition strengthens and expands Ottobock's position in neuro-orthopedics, but because Fesia is small it is likely to have only a limited impact on revenue and operating profit. The deal is mainly considered strategic. » Plus sur finanzen.net